Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AVNSNASDAQ:LMATNASDAQ:NVCRNYSE:WRBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVNSAvanos Medical$12.58-0.5%$12.81$11.84▼$25.36$581.75M1.13365,271 shs415,935 shsLMATLeMaitre Vascular$82.17+1.4%$83.86$71.42▼$109.58$1.86B0.86168,628 shs166,962 shsNVCRNovoCure$18.87-2.7%$17.51$14.17▼$34.13$2.10B0.731.14 million shs1.11 million shsWRBYWarby Parker$21.20+2.1%$17.04$12.46▼$28.68$2.17B2.011.92 million shs2.96 million shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVNSAvanos Medical0.00%+2.15%+1.99%-16.50%-34.89%LMATLeMaitre Vascular0.00%+0.95%-8.94%-10.54%+4.49%NVCRNovoCure0.00%+1.78%+5.13%-1.05%-14.27%WRBYWarby Parker0.00%+6.85%+28.76%-14.42%+26.27%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVNSAvanos Medical2.2094 of 5 stars0.03.00.00.01.92.52.5LMATLeMaitre Vascular2.7563 of 5 stars2.21.04.20.03.02.51.3NVCRNovoCure3.6531 of 5 stars3.32.00.04.52.31.70.0WRBYWarby Parker2.37 of 5 stars2.32.00.00.03.94.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVNSAvanos Medical 0.00N/AN/AN/ALMATLeMaitre Vascular 2.33Hold$97.8319.06% UpsideNVCRNovoCure 2.67Moderate Buy$32.8374.00% UpsideWRBYWarby Parker 2.61Moderate Buy$22.887.90% UpsideCurrent Analyst Ratings BreakdownLatest AVNS, WRBY, NVCR, and LMAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025WRBYWarby ParkerPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$20.00 ➝ $25.005/22/2025WRBYWarby ParkerRoth CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$18.00 ➝ $21.005/21/2025WRBYWarby ParkerCowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025WRBYWarby ParkerLoop CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/21/2025WRBYWarby ParkerCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$17.00 ➝ $22.005/21/2025WRBYWarby ParkerStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetHold ➝ Hold$18.00 ➝ $21.005/21/2025WRBYWarby ParkerTD SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $24.005/13/2025WRBYWarby ParkerUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$23.00 ➝ $20.005/9/2025WRBYWarby ParkerThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.005/9/2025WRBYWarby ParkerTelsey Advisory GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $22.004/23/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.00(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVNSAvanos Medical$689.20M0.84$1.65 per share7.64$26.63 per share0.47LMATLeMaitre Vascular$226.26M8.21$1.45 per share56.52$13.38 per share6.14NVCRNovoCure$621.71M3.38N/AN/A$3.39 per share5.57WRBYWarby Parker$795.09M2.79N/AN/A$3.08 per share6.88Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVNSAvanos Medical-$61.80M-$8.3737.007.27N/A2.30%4.70%3.46%7/30/2025 (Estimated)LMATLeMaitre Vascular$30.10M$1.9844.9037.872.2219.40%13.15%11.47%8/7/2025 (Estimated)NVCRNovoCure-$207.04M-$1.51N/AN/AN/A-25.93%-41.48%-12.74%7/24/2025 (Estimated)WRBYWarby Parker-$63.20M-$0.12N/A212.00N/A-4.39%-8.26%-4.37%8/14/2025 (Estimated)Latest AVNS, WRBY, NVCR, and LMAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/6/2025Q1 2025AVNSAvanos Medical$0.19$0.26+$0.07$0.14$161.75 million$167.50 million5/1/2025Q1 2025LMATLeMaitre Vascular$0.50$0.48-$0.02$0.48$57.61 million$59.87 million4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVNSAvanos MedicalN/AN/AN/AN/AN/ALMATLeMaitre Vascular$0.800.97%+13.30%40.40%14 YearsNVCRNovoCureN/AN/AN/AN/AN/AWRBYWarby ParkerN/AN/AN/AN/AN/ALatest AVNS, WRBY, NVCR, and LMAT DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date4/29/2025LMATLeMaitre Vascularquarterly$0.201%5/15/20255/15/20255/29/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVNSAvanos Medical0.122.221.46LMATLeMaitre VascularN/A7.745.52NVCRNovoCure0.271.491.44WRBYWarby ParkerN/A2.472.06Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVNSAvanos Medical95.17%LMATLeMaitre Vascular84.64%NVCRNovoCure84.61%WRBYWarby Parker93.24%Insider OwnershipCompanyInsider OwnershipAVNSAvanos Medical2.64%LMATLeMaitre Vascular9.50%NVCRNovoCure6.29%WRBYWarby Parker26.55%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVNSAvanos Medical4,04046.24 million44.15 millionOptionableLMATLeMaitre Vascular49022.59 million20.06 millionOptionableNVCRNovoCure1,320111.49 million101.40 millionOptionableWRBYWarby Parker3,030104.50 million74.67 millionOptionableAVNS, WRBY, NVCR, and LMAT HeadlinesRecent News About These CompaniesWarby Parker (NYSE:WRBY) Trading Up 3% - Still a Buy?May 31 at 12:48 PM | marketbeat.comInsider Selling: Warby Parker Inc. (NYSE:WRBY) Director Sells 33,073 Shares of StockMay 29 at 7:40 PM | marketbeat.comTwo Sigma Advisers LP Increases Stake in Warby Parker Inc. (NYSE:WRBY)May 29 at 3:58 AM | marketbeat.comGoogle Is Back to Smart Glasses: This Time It Might WorkMay 28, 2025 | techopedia.comYoungme E. Moon Sells 33,073 Shares of Warby Parker Inc. (NYSE:WRBY) StockMay 28, 2025 | insidertrades.comWarby Parker Inc. (NYSE:WRBY) Shares Acquired by Two Sigma Investments LPMay 28, 2025 | marketbeat.comLoop Capital Maintains Buy Rating on Warby Parker (WRBY) StockMay 27, 2025 | insidermonkey.comWoodline Partners LP Sells 85,914 Shares of Warby Parker Inc. (NYSE:WRBY)May 27, 2025 | marketbeat.comMan Group plc Sells 18,862 Shares of Warby Parker Inc. (NYSE:WRBY)May 27, 2025 | marketbeat.comWarby Parker Inc. (NYSE:WRBY) Shares Sold by Millennium Management LLCMay 27, 2025 | marketbeat.comWarby Parker FY2026 EPS Forecast Increased by Roth CapitalMay 27, 2025 | marketbeat.comBank of America Corp DE Increases Position in Warby Parker Inc. (NYSE:WRBY)May 26, 2025 | marketbeat.comFY2026 EPS Estimate for Warby Parker Increased by AnalystMay 26, 2025 | americanbankingnews.comQ3 Earnings Estimate for Warby Parker Issued By Roth CapitalMay 25, 2025 | marketbeat.comQ3 Earnings Forecast for Warby Parker Issued By Roth CapitalMay 25, 2025 | americanbankingnews.comWarby Parker (NYSE:WRBY) Price Target Raised to $21.00May 24, 2025 | marketbeat.comCastleark Management LLC Invests $4.29 Million in Warby Parker Inc. (NYSE:WRBY)May 24, 2025 | marketbeat.comWarby Parker (NYSE:WRBY) Stock Price Expected to Rise, TD Securities Analyst SaysMay 24, 2025 | americanbankingnews.comWarby Parker (WRBY) Joins AI Race, Google Backs Smart Glasses ProjectMay 23, 2025 | insidermonkey.comWarby Parker (NYSE:WRBY) Sees Strong Trading Volume After Analyst UpgradeMay 23, 2025 | marketbeat.comWarby Parker teams with Google. Is the stock a buy?May 23, 2025 | cantechletter.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAVNS, WRBY, NVCR, and LMAT Company DescriptionsAvanos Medical NYSE:AVNS$12.58 -0.06 (-0.47%) Closing price 05/30/2025 03:59 PM EasternExtended Trading$13.54 +0.96 (+7.62%) As of 05/30/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.LeMaitre Vascular NASDAQ:LMAT$82.17 +1.10 (+1.36%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$82.27 +0.10 (+0.12%) As of 05/30/2025 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.NovoCure NASDAQ:NVCR$18.87 -0.53 (-2.73%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$18.64 -0.23 (-1.21%) As of 05/30/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Warby Parker NYSE:WRBY$21.20 +0.44 (+2.12%) Closing price 05/30/2025 03:59 PM EasternExtended Trading$21.20 +0.00 (+0.02%) As of 05/30/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Warby Parker Inc. provides eyewear products in the United States and Canada. The company offers eyeglasses, sunglasses, light-responsive lenses, blue-light-filtering lenses, non-prescription lenses, and contact lenses. It also provides accessories, such as cases, lenses kit with anti-fog spray, pouches, and anti-fog lens spray through its retail stores, website, and mobile apps. In addition, the company offers eye exams and vision tests. Warby Parker Inc. was incorporated in 2009 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Archer Aviation Stock Steadies After Short-Seller Report Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
